New Jersey-based Eagle Pharmaceuticals, a company geared towards pharmaceutical hospital sales, finalized terms to acquire Acacia Pharma.

Shares of Acacia Pharma skyrocketed in trading after the company announced FDA approval for Barhemsys (amisulpride injection) for the prevention and treatment of postoperative nausea and vomiting (PONV) in adults.